1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MedCap AB

MedCap AB

546.00
SEK
+2.00
(+0.37%)
16.23EPS
32.35P/E
7.85BMarket Cap
Oct 23Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
68.18
63.84
60.96
63.55
30.68
52.8
56.29
56.96
61.9
75.06
107.2
121.93
140.67
151.71
Basic EPS, GAAP
1.87
0.64
1.45
0.01
0.16
0.04
3.99
4.24
6.52
7.94
11.63
14
14.67
16.21
Free Cash Flow per Basic Share
-2.03
-1.14
-2.07
3.34
0.69
4.2
3.06
6.35
3.74
2.78
12.74
19.82
18.72
22.13
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
17.25
19.91
21.03
20.21
19.76
20.17
24.37
40.26
47
57.83
69.08
85.62
96.68
105.91
Tangible Book Value per Share
2.75
6.94
5.78
4.32
3.99
-3.06
-1.83
9.28
17.43
28.02
25.24
41.07
14.85
14.29
Basic Weighted Avg Shares
12
13
13
13
13
13
13
14
15
15
15
15
15
15
Sales/Revenue/Turnover
826
853
817
852
411
709
757
817
916
1,111
1,587
1,807
2,108
2,276
Operating Margin (%)
3.31
4.41
3.44
0.2
3.55
6.28
10.43
9.86
11.78
13.42
13.57
13.34
13.7
15.38
Depreciation Expense
25
20
23
27
30
34
57
68
76
88
104
115
153
175
Net Income, GAAP
23
9
19
- -
2
1
54
61
97
118
172
207
220
243
Effective Tax Rate (%)
1.59
19.51
15.2
- -
58.62
34.33
20.22
20.86
16.15
22.37
22.4
19.99
23.63
22.77
Profit Margin (%)
2.74
1
2.38
0.01
0.51
0.08
7.09
7.45
10.53
10.58
10.85
11.48
10.43
10.69
Working Capital
70
114
141
71
80
17
-22
167
233
440
422
586
497
472
LT Debt
29
12
55
19
49
65
158
157
165
224
192
297
381
370
Total Equity
222
281
308
292
268
274
333
602
698
859
1,027
1,288
1,459
1,588
Return on Invested Capital (%)
8.73
2.07
-1.22
- -
-0.17
6.48
11.89
9.09
11.52
12.11
13.77
14.35
12.55
14.19
Return on Capital (%)
7.7
2.62
5.1
- -
0.68
0.24
10.74
8.69
11.29
12.07
14.8
15.01
13.54
15.1
Return on Common Equity (%)
11.47
3.58
7.09
0.03
0.78
0.22
17.93
13.19
14.94
15.15
18.33
18
16.08
16.82

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
102
88
88
LT Borrowings
157
174
162
LT Finance Leases
224
217
208
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
8,246
7,021
7,855

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
991
1,092
1,021
Cash, Cash Equivalents & STI
370
394
286
Accounts Receivable, Net
267
371
387
Inventories
271
296
298
Total Current Liabilities
495
520
548
Payables & Accruals
- -
- -
- -
ST Debt
102
88
88
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.84%
19.45%
13.25%
Free Cash Flow
60.49%
68.86%
-4.49%
Net Income, GAAP
1,162.22%
30.64%
5.98%
Sales/Revenue/Turnover
14.64%
21.34%
16.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
462
458
413
474
1,807
2025
494
522
- -
591
2,108
2026
557
606
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.78
3.84
3.57
2.8
14
2025
3.37
3.57
- -
4.31
14.67
2026
3.72
4.61
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anders Dahlberg
Full Time Employees
637
Sector
Health technology
Industry
Medical specialties
Address
Engelbrektsgatan 9 Stockholm AB Sweden 114 32
IPO Date
Jul 4, 2006
Website
medcap.se
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
MedCap AB (publ) (MCAP.ST) is a Sweden-based investment company that acquires, develops and owns profitable niche companies within the life science sector, focusing on assistive technology, medical technology (MedTech) and specialty pharmaceuticals. Founded in 2001 and headquartered in Solna, Stockholm, the group operates primarily in Northern Europe, with sales distributed across Sweden (50%), other Nordic countries (25%), broader Europe (21%) and the rest of the world (4%); its portfolio companies serve regions, municipalities, healthcare providers, property owners and end-users. Core offerings span three business areas: Assistive Tech, including digital and physical aids for cognition, communication, environmental control, alarms, mobility, accessibility and orthotics through subsidiaries such as Abilia (Nordic, UK, exports), Trident (Sweden, Europe), Huka (Benelux, Nordic, Germany, USA), Erimed (Nordic, exports) and Danrehab (Nordic, Benelux, Europe); MedTech, encompassing medical devices, healthcare equipment, packaging solutions for life science products, contract manufacturing of probiotics and nutrition supplements, carbon fiber components and clean air equipment for operating rooms via companies like Inpac (Nordic), Multi-Ply (global), SurgiCube (global), Toul Meditech (global) and Cardiolex (Europe); and Specialty Pharma, featuring specialty pharmaceuticals, contract development and manufacturing organization (CDMO) services and medicines in licensed, extemporaneous and non-licensed classifications through Unimedic (Northern Europe). In 2025, MedCap completed three key acquisitions to drive growth and expand offerings: Danrehab in Assistive Tech, XGX Pharma in Specialty Pharma on July 21 (enhancing registered pharmaceuticals and commercial portfolio via Unimedic collaboration), and LivAssured by subsidiary Abilia on October 1 (adding Nightwatch epileptic seizure detection device, initially for EUR 9.5 million plus deferred and potential earn-out payments up to EUR 4 million); these moves contributed to Q3 2025 net sales growth of 21% (9% organic), adjusted EBITA up 32% to SEK 91.1 million and strengthened market positions across segments.